A Phase II Clinical Trial of Vinorelbine in Dogs with Cutaneous Mast Cell Tumors

Abstract

Vinorelbine was associated with an overall response rate of 13% and a high prevalence of neutropenia. Additional studies are indicated to determine if repeated dosing of vinorelbine or combination of vinorelbine with other drugs increases the observed biologic activity against canine MCT.